Chiasma (NASDAQ:CHMA) had its price objective upped by stock analysts at Piper Sandler from to in a note issued to investors on Tuesday, The Fly reports. The firm currently has an “overweight” rating on the biotechnology company’s stock.
Several other brokerages have also weighed in on CHMA. ValuEngine raised Chiasma from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. Zacks Investment Research lowered Chiasma from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Chiasma in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $12.42.
Shares of Chiasma stock traded up $0.43 during trading hours on Tuesday, reaching $5.17. 659,700 shares of the company’s stock were exchanged, compared to its average volume of 512,056. Chiasma has a 52-week low of $3.20 and a 52-week high of $9.25. The firm has a market capitalization of $199.18 million, a price-to-earnings ratio of -4.04 and a beta of 1.16. The company has a fifty day moving average of $5.19 and a 200-day moving average of $5.45.
Chiasma (NASDAQ:CHMA) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. As a group, equities analysts forecast that Chiasma will post -1.03 EPS for the current year.
In related news, Director Roni Mamluk sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $4.94, for a total value of $49,400.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $49,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 8.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in CHMA. Point72 Asset Management L.P. acquired a new stake in shares of Chiasma during the third quarter valued at about $8,014,000. BlackRock Inc. raised its holdings in shares of Chiasma by 868.1% during the second quarter. BlackRock Inc. now owns 1,601,272 shares of the biotechnology company’s stock valued at $11,962,000 after buying an additional 1,435,873 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Chiasma by 30.9% during the second quarter. Vanguard Group Inc. now owns 1,051,908 shares of the biotechnology company’s stock valued at $7,858,000 after buying an additional 248,574 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Chiasma by 85.2% during the second quarter. Renaissance Technologies LLC now owns 411,883 shares of the biotechnology company’s stock valued at $3,077,000 after buying an additional 189,500 shares during the last quarter. Finally, State Street Corp raised its holdings in Chiasma by 39.2% during the third quarter. State Street Corp now owns 536,475 shares of the biotechnology company’s stock worth $2,656,000 after purchasing an additional 151,121 shares in the last quarter. 74.45% of the stock is currently owned by institutional investors.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
See Also: What is a Tariff?
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.